1. Summary Information
|
|
|
Country |
|
|
Company Name |
SHANTHA BIOTECHNICS LIMITED |
Principal Name 1 |
Mr.Harish Venkatachalam Iyer |
|
Status |
Moderate |
Principal Name 2 |
Mr.Koduru Iswara Varaprasad Reddy |
|
|
|
Registration # |
21-074872 |
|
Street Address |
3rd and 4th Floors, H.No.5-10-173, |
||
|
Established Date |
10.03.1993 |
SIC Code |
-- |
|
Telephone# |
91-40-23234104 / 23234105/ 23234136 |
Business Style 1 |
Manufacturing |
|
Fax # |
91-40-23234133 |
Business Style 2 |
-- |
|
Homepage |
Product Name 1 |
Hepatits B Vaccine |
|
|
# of employees |
300 (Approximately) |
Product Name 2 |
Alpha Interferon |
|
Paid up capital |
Rs. 162,306,000/- |
Product Name 3 |
Restriction Enzymes |
|
Shareholders |
Foreign holdings-96.43% Directors or relative of directors-3.44% Others-0.13% |
Banking |
State Bank of |
|
Public Limited Corp. |
No |
Business Period |
19 Years |
|
IPO |
No |
International Ins. |
- |
|
Public |
No |
Rating |
B (29) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
Subsidiaries |
|
Shantha West INC |
-- |
|
Note |
-- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
564,021,000 |
Current Liabilities |
1351,692,000 |
|
Inventories |
391,415,000 |
Long-term Liabilities |
2224,451,000
|
|
Fixed Assets |
1931,257,000 |
Other Liabilities |
192,292,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
3,768,435,000 |
|
Invest& other Assets |
1095,774,000 |
Retained Earnings |
1230,428,000 |
|
|
|
Net Worth |
214,032,000 |
|
Total Assets |
3,982,467,000 |
Total Liab. & Equity |
3982,467,000 |
|
Total Assets (Previous Year) |
4,124,082,000 |
|
|
|
P/L Statement as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Sales |
441,757,000 |
Net Profit |
(1609,280,000) |
|
Sales(Previous yr) |
1,883,045,000 |
Net Profit(Prev.yr) |
(154,452,000) |
|
Report Date : |
10s.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
SHANTHA BIOTECHNICS LIMITED |
|
|
|
|
Formerly Known
As : |
SHANTHA BIOTECHNICS PRIVATE LIMITED |
|
|
|
|
Registered Office
: |
3rd and 4th Floors, H.No.5-10-173, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
10.03.1993 |
|
|
|
|
Com. Reg. No.: |
01-015470 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 162.306 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24110AP1993PLC015470 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
HYDS07760E |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAECS6982Q |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company. |
|
|
|
|
Line of Business
: |
Manufacturing of Hepatitis B Vaccine, Alpha Interferon, and
Restriction Enzymes. |
|
|
|
|
No. of Employees
: |
300 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
B (29) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
Maximum Credit Limit : |
USD 850000 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having moderate track. There
appear huge accumulated losses recorded by the company. Profitability of the
company is under pressure. However, trade relations are reported as fair.
Business is active. Payments are reported to be slow but correct. The company can be considered for business dealings with some caution. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office : |
3rd and 4th Floors, H.No.5-10-173, |
|
Tel. No.: |
91-40-23234104/ 23234105/ 23234136/ 66301000 |
|
Fax No.: |
91-40-23234133/ 23234103 |
|
E-Mail : |
|
|
Website: |
|
|
|
|
|
Medchal Office : |
Post Box No. 4, Medchal, |
|
Tel. No.: |
91-418-2222922 / 2222693 / 2222694 / 2222695 |
|
|
|
|
Corporate Office : |
8-2-334, Serene Chambers, 3rd Floor, Road No. 5,
Banjarahills, |
|
Tel. No.: |
91-40-23543010/ 23548507/ 23608843 |
|
Fax No.: |
91-40-23548476 |
|
E-Mail : |
|
|
|
|
|
Regional Office 1 : |
208 Parkway Drive, |
|
Tel. No.: |
91-516-8593010 |
|
Fax No.: |
91-516-6263032 |
|
E-Mail : |
|
|
|
|
|
Regional Office 2 : |
|
|
Tel. No.: |
91-858-6589450 |
|
Fax No.: |
91-858-6589230 |
|
E-Mail : |
|
|
|
|
|
Branches : |
Located at: |
|
|
G-1, Saikamala Nivas, Padmarao Nagar, Secunderbad – 500003, Tel. 91-40-26211371 3rd Floor, Serene Tel. 91-40-26502866/26502868 Flat No. 101, Gayatri (West), Tel. 91-40-26570215 203, Ridge Wood Residency (West), Maredpally, Secunderabad – 500036, Tel. 91-40-26211285 202, Maitri Nivas, B. S. Martha, Begumpet, |
DIRECTORS
AS ON 30.08.2011
|
Name : |
Mr. Harish Venkatachalam Iyer |
|
Designation : |
Managing Director |
|
Address : |
Plot no 26, |
|
Date of Birth/Age : |
22.10.1969 |
|
Date of Appointment : |
13.06.2011 |
|
DIN No.: |
02744989 |
Other Directorship:
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U73100KA2008PLC046583 |
BIOCON RESEARCH
LIMITED |
Director |
22-07-10 |
24-08-09 |
23-05-11 |
Active |
NO |
|
2 |
U24110AP1993PLC015470 |
SHANTHA
BIOTECHNICS LIMITED |
Managing
director |
30-08-11 |
13-06-11 |
- |
Active |
NO |
|
Name : |
Mr. Koduru Iswara Varaprasad Reddy |
|
Designation : |
Director |
|
Address : |
Plot no.822, Road No.40, Jubilee Hills, |
|
Date of Birth/Age : |
30.06.1947 |
|
Date of Appointment : |
13.06.2011 |
|
DIN No.: |
00196148 |
Other Directorship:
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U21011AP1991PTC012978 |
TRUST HOUSE
TECHNICAL SERVICES PRIVATE LIMITED |
Director |
22-07-91 |
22-07-91 |
12-11-10 |
Active |
NO |
|
2 |
U24110AP1993PLC015470 |
SHANTHA
BIOTECHNICS LIMITED |
Director |
30-08-11 |
10-03-93 |
- |
Active |
NO |
|
3 |
U72200AP1992PLC014675 |
ANANTH
TECHNOLOGIES LIMITED |
Director |
01-06-93 |
01-06-93 |
13-11-09 |
Active |
NO |
|
4 |
U65993AP1995PTC019842 |
SVAS INVESTMENTS
PRIVATE LIMITED |
Director |
28-03-95 |
28-03-95 |
- |
Active |
NO |
|
5 |
U10200AP1995PTC018574 |
MERICLONE BIOLUK
PRIVATE LIMITED |
Director |
29-09-95 |
29-09-95 |
- |
Strike off |
NO |
|
6 |
U31300AP1996PTC026016 |
INDUS INSUL
PRIVATE LIMITED |
Director |
23-12-96 |
23-12-96 |
- |
Active |
NO |
|
7 |
U31909DD1998PLC004665 |
NED ENERGY
LIMITED |
Director |
11-12-98 |
11-12-98 |
29-09-07 |
Active |
NO |
|
8 |
U24232AP2007PTC052719 |
SPARSHA PHARMA
INTERNATIONAL PRIVATE LIMITED |
Director |
12-02-07 |
12-02-07 |
- |
Active |
NO |
|
9 |
U85100AP2008PTC062090 |
SARVEJANA
HEALTHCARE PRIVATE LIMITED |
Director |
30-09-09 |
11-01-09 |
- |
Active |
NO |
|
10 |
U24100AP2009PTC062594 |
INDIAN INSTITUTE
OF BIOTECHNOLOGY PRIVATE LIMITED |
Director |
23-01-09 |
23-01-09 |
- |
Active |
NO |
|
Name : |
Mr. Shailesh Ayyangar |
|
Designation : |
Director |
|
Address : |
A7, Rashmi, |
|
Date of Birth/Age : |
15.10.1954 |
|
Date of Appointment : |
13.06.2011 |
|
DIN No.: |
00268076 |
Other Directorship:
|
S.No. |
CIN |
Name of the Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U24230MH1997PTC111122 |
CHIRON BEHRING
VACCINES PRIVATE LIMITED |
Nominee director |
21-10-05 |
21-10-05 |
08-07-09 |
Active |
NO |
|
2 |
L24239MH1956PLC009794 |
AVENTIS PHARMA
LIMITED |
Managing
director |
25-10-10 |
25-10-05 |
- |
Active |
NO |
|
3 |
U24230MH2002PLC137682 |
SANOFI-SYNTHELABO
( |
Managing director |
18-11-10 |
18-11-05 |
- |
Active |
NO |
|
4 |
U91120MH1965GAP013389 |
ORGANISATION OF
PHARMACEUTICAL PRODUCERS OF |
Director |
23-09-06 |
23-09-06 |
- |
Active |
NO |
|
5 |
U24232MH1996PTC205997 |
SANOFI PASTEUR
INDIA PRIVATE LIMITED |
Director |
25-06-09 |
22-06-09 |
02-07-09 |
Active |
NO |
|
6 |
U74999MH1924NPL001128 |
|
Director |
09-06-10 |
09-06-10 |
13-09-11 |
Active |
NO |
|
7 |
U24110AP1993PLC015470 |
SHANTHA
BIOTECHNICS LIMITED |
Director |
30-08-11 |
13-06-11 |
- |
Active |
NO |
|
Name : |
Mr. Olivier Charmeil |
|
Designation : |
Director |
|
Address : |
75, Rue De Courcelles, |
|
Date of Birth/Age : |
19.02.1963 |
|
Date of Appointment : |
03.09.2009 |
|
DIN No.: |
00370311 |
Other Directorship:
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U24230MH2002PLC137682 |
SANOFI-SYNTHELABO
( |
Director |
24-02-06 |
24-02-06 |
07-04-11 |
Active |
NO |
|
2 |
L24239MH1956PLC009794 |
AVENTIS PHARMA
LIMITED |
Director
appointed in casual vacancy |
30-10-06 |
30-10-06 |
23-08-11 |
Active |
NO |
|
3 |
U24110AP1993PLC015470 |
SHANTHA
BIOTECHNICS LIMITED |
Director |
30-09-10 |
03-09-09 |
- |
Active |
NO |
|
Name : |
Mr. Jean Louis Grunwald |
|
Designation : |
Director |
|
Address : |
|
|
Date of Birth/Age : |
20.05.1961 |
|
Date of Appointment : |
13.06.2011 |
|
DIN No.: |
00570064 |
Other Directorship:
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
L24239MH1956PLC009794 |
AVENTIS PHARMA
LIMITED |
Alternate
director |
02-09-09 |
10-11-06 |
27-10-09 |
Active |
NO |
|
2 |
U24232MH1996PTC205997 |
SANOFI PASTEUR
INDIA PRIVATE LIMITED |
Additional
director |
25-11-10 |
25-11-10 |
12-06-11 |
Active |
NO |
|
3 |
U24110AP1993PLC015470 |
SHANTHA
BIOTECHNICS LIMITED |
Director |
30-08-11 |
13-06-11 |
- |
Active |
NO |
KEY EXECUTIVES
|
Name : |
Mr. Rajashekhar Narayanasamy |
|
Designation : |
Company Secretary |
|
Address : |
7-1-63/2, Flat
No. 105, Maitri Enclave, |
|
Date of Birth/Age : |
14.08.1961 |
|
Date of Appointment : |
23.04.2001 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 30.08.2011
|
Names of Shareholders |
|
No. of Shares |
|
Thirupati Reddy Mallela,
Jointly Mrs. Prabhavathi Devi Mallela |
|
100 |
|
Archana Katti |
|
100 |
|
Kanuri Kavya |
|
100 |
|
Lubna |
|
185 |
|
Y Nagendra Prasad |
|
200 |
|
Dasari Anil Prabhu Kumar |
|
300 |
|
Vamsiraj R. Sanghamerddy |
|
500 |
|
B Venkateswar Reddy |
|
500 |
|
Gundepudi Venkata |
|
500 |
|
Uppalapati Venkateshwara Rao |
|
500 |
|
Suresh Kumar Kimtee |
|
500 |
|
V Kesamma |
|
500 |
|
Nallapati Hari Hara Prasad |
|
1000 |
|
Narendra Reddy Thappeta |
|
1000 |
|
A Vijay Lakshmi |
|
1000 |
|
Artula Vijaya Lakshmi |
|
1000 |
|
D vijayasri |
|
1000 |
|
G Madhava Kumar |
|
800 |
|
Tummala Prabhavathi |
|
1000 |
|
Subbineni Annapurna |
|
1000 |
|
Potherddy Srinivasulu Reddy |
|
1000 |
|
Narayanben Mukundal Khiraiya Jointly Mukundlal Vallabhdas Khairaiya |
|
1000 |
|
Devi Prasad Malladi |
|
1000 |
|
Rajnikanth Lalji Tanna, Jointly Nirmala Rajnikanth Tanna |
|
1000 |
|
Nissar Ahmed |
|
1000 |
|
Siddareddy Venturu |
|
2000 |
|
G Srilatha |
|
200 |
|
G Ravichandran |
|
2500 |
|
Shankar N. Planjery |
|
3100 |
|
K. Sravanthi |
|
26000 |
|
K I Varaprasad Reddy |
|
532770 |
|
K Vasantha |
|
10 |
|
K Shanthamma |
|
10 |
|
|
|
10 |
|
N Gautam Kumar |
|
10 |
|
J Sharath Reddy |
|
10 |
|
Sanofi Pasteru Merieux Sas, France |
|
15647155 |
|
Total |
|
16230560 |
AS ON 02.09.2011
|
Names of Allotees |
|
No. of Shares |
|
Sanofi Pasteur Merleux |
|
1012870 |
|
Thirupati Reddy Mallela Jointly Prabhavathi Devi Mallela |
|
6 |
|
Archana Katti |
|
6 |
|
Kanurj Kavya |
|
6 |
|
Uppalapathi Venkateshwara Rao |
|
31 |
|
Suresh Kumar Kimtee |
|
31 |
|
V.Kesamma |
|
31 |
|
Nallapati Hari Hara Prasad |
|
63 |
|
Pothe Reddy Shrinivasulu Reddy |
|
63 |
|
Total |
|
1013107 |
AS ON 30.08.2011
|
Equity Shares
Break Up |
Percentage |
|
Foreign holdings( Foreign institutional investor(s),
Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s)
or Overseas Corporate bodies or Others |
96.43 |
|
Directors or relatives of Directors |
3.44 |
|
Other top fifty shareholders |
0.13 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing of Hepatitis B Vaccine, Alpha Interferon, and
Restriction Enzymes. |
||||||||||||
|
Products : |
Diagnostic Kits
Streptokinase Injection
|
GENERAL INFORMATION
|
No. of Employees : |
300 (Approximately) |
||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
Bankers : |
·
State Bank of India, Plot No. 241/A, Road No. 36,
Rajala Towers, 2nd Floor and 3rd Floor, Jubilee Hills,
Hyderabad – 500033, Andhra Pradesh, India ·
IDBI Bank Limited, #5-9-89/1 and 2, |
||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address : |
Coromandel House, 1-2-10, |
|
PAN No.: |
AACFD3771D |
|
|
|
|
Fellow Subsidiaries : |
·
Sanofi Pasteur Merieur SAS, France ·
Sanofi Pasteur India Private Limited, ·
Aventis Pharma Limited, ·
·
Sanofi Pasteur SA, France ·
|
|
|
|
|
Ultimate Holding Company: |
·
Merieux |
|
|
|
|
Subsidiary Company: |
·
Shantha West INC, |
CAPITAL STRUCTURE
After 30.08.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
22000000 |
Equity Shares |
Rs.10/- each |
Rs.220.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
17243667 |
Equity Shares |
Rs.10/- each |
Rs. 172.437 Millions |
|
|
|
|
|
AS ON 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
22000000 |
Equity Shares |
Rs.10/- each |
Rs.220.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
16230560 |
Equity Shares |
Rs.10/- each |
Rs.162.306 Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
162.306 |
162.306 |
160.439 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1230.428 |
1661.005 |
1802.106 |
|
|
4] (Accumulated Losses) |
(1178.702) |
0.000 |
0.000 |
|
|
NETWORTH |
214.032 |
1823.311 |
1962.545 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
277.190 |
499.973 |
890.290 |
|
|
2] Unsecured Loans |
1947.261 |
109.212 |
110.821 |
|
|
TOTAL BORROWING |
2224.451 |
609.185 |
1001.111 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
117.019 |
119.740 |
|
|
STOCK OPTION OUTSTANDING |
0.000 |
0.000 |
5.379 |
|
|
TOTAL |
2438.483 |
2549.515 |
3088.775 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1931.257 |
1559.165 |
1564.258 |
|
|
Capital work-in-progress |
1095.604 |
323.093 |
252.285 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.170 |
719.090 |
719.090 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
391.415
|
342.271 |
375.914 |
|
|
Sundry Debtors |
67.261
|
232.021 |
543.404 |
|
|
Cash & Bank Balances |
258.286
|
650.933 |
139.052 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
238.474
|
297.509 |
143.027 |
|
Total
Current Assets |
955.436
|
1522.734 |
1201.397 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
299.055
|
311.089 |
335.332 |
|
|
Other Current Liabilities |
1052.637
|
1091.084 |
33.508 |
|
|
Provisions |
192.292
|
172.394 |
279.415 |
|
Total
Current Liabilities |
1543.984
|
1574.567 |
648.255 |
|
|
Net Current Assets |
(588.548)
|
(51.833) |
553.142 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
2438.483 |
2549.515 |
3088.775 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Sales |
441.757 |
1883.045 |
2025.605 |
|
|
|
Income from Contract Services |
20.444 |
14.895 |
38.509 |
|
|
|
Other Income |
112.735 |
35.907 |
33.802 |
|
|
|
TOTAL |
574.936 |
1933.847 |
2097.916 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Consumption Material changes Inventories |
317.689 |
622.327 |
1345.656 |
|
|
|
Manufacturing service costs |
188.775 |
279.677 |
(13.558) |
|
|
|
Employee related expense |
293.547 |
305.234 |
0.000 |
|
|
|
Administrative selling and other expense |
269.522 |
379.267 |
0.000 |
|
|
|
Research Development expenditure |
149.258 |
164.769 |
0.000 |
|
|
|
Restructuring Charges |
0.000 |
145.323 |
0.000 |
|
Add |
|
Exceptional Income charges |
768.881 |
25.100 |
35.000 |
|
|
|
TOTAL |
1987.672 |
1921.697 |
1367.098 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION |
(1412.736) |
12.150 |
730.818 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES |
105.212 |
66.790 |
87.383 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION |
(1517.948) |
(54.640) |
643.435 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
117.621 |
102.503 |
83.998 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
(1635.569) |
(157.143) |
559.437 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
26.289 |
(2.691) |
34.876 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX |
(1609.280) |
(154.452) |
524.561 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
430.578 |
585.030 |
308.175 |
|
|
|
|
|
|
|
|
|
Less |
Appropriation |
0.000 |
0.000 |
247.706 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
(1178.702) |
430.578 |
585.030 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.)
Basic: |
(99.15) |
(9.56) |
32.88 |
|
|
|
Diluted: |
(99.15) |
(9.56) |
32.88 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
(279.91)
|
(7.99) |
25.00 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
(370.24)
|
(8.35) |
27.62 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
(56.66)
|
(5.10) |
20.23 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
(7.64)
|
(0.09) |
0.29 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
17.61
|
1.20 |
0.84 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
0.62
|
0.97 |
1.85 |
LOCAL AGENCY FURTHER INFORMATION
|
Check List by Info Agents |
Available in Report (Yes / No) |
|
1. Year of Establishment |
Yes |
|
2. Locality of the firm |
Yes |
|
3. Constructions of the firm |
Yes |
|
4. Premises details |
No |
|
5. Type of Business |
Yes |
|
6. Line of Business |
Yes |
|
7. Promoter’s background |
Yes |
|
8. No. of Employees |
No |
|
9. Name of person contacted |
No |
|
10. Designation of contact person |
No |
|
11. Turnover of firm for last three years |
Yes |
|
12. Profitability for last three years |
Yes |
|
13. Reasons for variation <> 20% |
-- |
|
14. Estimation for coming financial year |
No |
|
15. Capital in the business |
Yes |
|
16. Details of sister concerns |
Yes |
|
17. Major suppliers |
No |
|
18. Major customers |
No |
|
19. Payments terms |
No |
|
20. Export / Import details |
No |
|
21. Market information |
-- |
|
22. Litigations that the firm / promoter involved |
-- |
|
23. Banking Details |
Yes |
|
24. Banking facility details |
Yes |
|
25. Conduct of the banking account |
-- |
|
26. Buyer visit details |
-- |
|
27. Financials, if provided |
Yes |
|
28. Incorporation details, if applicable |
Yes |
|
29. Last accounts filed at ROC |
Yes |
|
30. Major Shareholders, if available |
Yes |
Bankers Charges
Report as per Registry
|
Corporate
identity number of the company |
U24110AP1993PLC015470 |
|
Name of the
company |
SHANTHA
BIOTECHNICS LIMITED |
|
Address of the registered
office or of the principal place of
business in |
3rd & 4th
Floors, H.No.5-10-173, |
|
This form is for |
Modification of
charge |
|
Type of charge |
Book debts Movable property
(not being pledge) |
|
Particular of
charge holder |
State Bank of Email ID: sbi.01921@sbi.co.in |
|
Nature of
instrument creating charge |
No Documents have
been executed |
|
Date of
instrument Creating the charge |
04.08.2011 |
|
Amount secured by
the charge |
Rs. 92.500
Millions |
|
Brief of the
principal terms an conditions and extent and operation of the charge |
Rate of interest No Change in
Other Terms and Conditions Terms of repayment No Change in
Other Terms and Conditions Margin No Change in
Other Terms and Conditions Extent and operation of the charge No Change in
Other Terms and Conditions |
|
Short particulars
of the property charged (Including location of the property) |
No Change in
Other Terms and Conditions |
|
Charge
identification number of the charge to be modified |
80021486 |
|
Date of
instrument modifying the charge |
Not Available |
|
Particulars of
the present modification |
The Existing
Limits have been reduced from Rs. 242.500 millions to Rs. 92.500 millions on
repayment of term loan of Rs. 150.000 millions. |
AS PER WEBSITE DETAILS:
ORAL CHOLERA VACCINE:
First licensed vaccine developed with Gates Foundation support
Efforts to accelerate the global use of new
generation cholera vaccines gained significant momentum with the licensure of a
new oral cholera vaccine, Shanchol in
IVI scientists developed this vaccine, with funding from the Bill &
Melinda Gates Foundation, the Government of Korea, and the Swedish
International Development Cooperation Agency (SIDA), by significantly modifying
a vaccine used and produced only in
Following field trials in
The IVI aims to make this vaccine available
for use in public health programs in
First, it does not require administration with a buffer, thereby greatly
simplifying its use under field conditions, including in refugee camps and
other post-crisis situations. Second, it will be available to governments and
international agencies at low cost (e.g., ≈$1.00 per dose with sufficient
demand). Third, a large efficacy trial taking place in
Growing momentum for use of oral cholera vaccines
The licensing in India of Shanchol has added considerably to the
momentum for the use of oral cholera vaccines to control endemic and epidemic
cholera. The increased interest among policymakers in cholera immunization has
also been prompted by the increased frequency of large, protracted and often
uncontrolled cholera epidemics in Zimbabwe and other African and Asian
countries in the past few years, and by fears that cholera incidence and
severity is increasing, due to global warming, growing urbanization, and the
increasing strain that urban migration and growth in slums are putting on
already inadequate water and sanitation systems.
In April 2009 policymakers in
The study will compare the effectiveness of vaccination (against a
control group) and of household water treatment methods and health promotion activities.
The IVI is providing technical assistance for the project. The government of
Of critical importance, the WHO Strategic Advisory Group of Experts
(SAGE), which plays a key role in making recommendations to WHO on the
introduction of new vaccines, held a session on cholera vaccines at its meeting
in October 2009. The results of much of the IVI's work in cholera - including
disease burden and economic studies, the laboratory and clinical development of
the Shanchol vaccine, and vaccine trials and demonstration projects - were
presented during the session and in a background paper prepared for the
meeting. Two IVI staff members also served on the ad hoc Working Group on
Cholera Vaccines that prepared the paper and presentations for the meeting. As
a result of this meeting, WHO will issue new, updated recommendations for the
use of cholera vaccines in a Position Paper to be published in 2010. These
recommendations should help stimulate increased interest among countries in
using cholera vaccines in high-risk areas, and among donor and technical
agencies in supporting their use.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 52.46 |
|
|
1 |
Rs. 85.27 |
|
Euro |
1 |
Rs. 69.40 |
INFORMATION DETAILS
|
Report Prepared
by : |
BVA |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
- |
|
--LIQUIDITY |
1~10 |
- |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
3 |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
29 |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.